Clinical implications of repeated drug monitoring of imatinib in patients with metastatic gastrointestinal stromal tumour

ConclusionsOur results do not support repeated monitoring of IM levels on a routine basis in all patients. However, we have revealed clinical scenarios where drug measurement could be beneficial, such as for patients who have undergone gastric resection, suspicion of non-compliance, subjectively reported side effects, in elderly patients and at the time of disease progression.
Source: Clinical Sarcoma Research - Category: Cancer & Oncology Source Type: research